medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-15-44-52medsovet-2670Research ArticleБронхиальная астмаBronchial asthmaТяжелая эозинофильная бронхиальная астма: новые возможности терапииSevere eosinophilic bronchial asthma: new therapeutic optionsНенашеваН. А.NenashevaN. M.

Ненашева Наталья Михайловна – доктор медицинских наук, профессор кафедры клинической аллергологии.

Москва

Moscow

ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияBudgetary Educational Institution of Further Professional Education of the Ministry of Russian Medical Academy of Continuing Postgraduate Education, Federal State Health of RussiaRussian Federation2018111020180154452Copyright © Ненашева Н.А., 20182018Ненашева Н.А.Nenasheva N.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2670

Эозинофильная астма является распространенным фенотипом тяжелой астмы и встречается по крайней мере у половины пациентов. За последнее время произошли существенные изменения в подходах к лечению тяжелой бронхиальной астмы, и прежде всего эозинофильной астмы. В статье обсуждаются вопросы роли эозинофилов в патогенезе тяжелой астмы, выявления фенотипа тяжелой эозинофильной астмы и современные подходы к таргетной терапии тяжелой астмы эозинофильного фенотипа с помощью биологических препаратов. Особый акцент сделан на препараты моноклональных антител к интерлейкину-5, в частности меполизумаб, недавно одобренный для клинического применения в нашей стране.

Eosinophilic asthma is a common phenotype of severe asthma, occurring in at least half of patients. In recent years, there have been significant changes in the approaches to the treatment of severe bronchial asthma and, above all, eosinophilic asthma. The article discusses the role of eosinophils in the pathogenesis of severe asthma, the detection of the phenotype of severe eosinophilic asthma, and modern approaches to targeting severe asthma with an eosinophilic phenotype using biological agents. A special emphasis is placed on preparations of monoclonal antibodies to interleukin-5, in particular, mepolizumab, recently approved for clinical use in our country.

эозинофилытяжелая эозинофильная астмабиологическая терапиямеполизумабeosinophilssevere eosinophilic asthmabiological therapymepolizumab.ReferencesTo T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet L-P. Global asthma prevalence in adults: findings from the crosssectional world health survey. BMC Public Health, 2012, 12: 204. https: //doi. org/10.1186/1471-2458-12-204.To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet L-P. Global asthma prevalence in adults: findings from the crosssectional world health survey. BMC Public Health, 2012, 12: 204. https: //doi. org/10.1186/1471-2458-12-204.Bousqet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol, 2010, 126: 926-38.Bousqet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol, 2010, 126: 926-38.Chung KF, Wenzel S, Brozek J et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43: 343–373Chung KF, Wenzel S, Brozek J et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43: 343–373Hyland ME, Whalley B, Jones RC, Masoli M. A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. Qual Life Res, 2015, 24: 631–9. https: //doi.org/10.1007/s11136-014-0801-x.Hyland ME, Whalley B, Jones RC, Masoli M. A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. Qual Life Res, 2015, 24: 631–9. https: //doi.org/10.1007/s11136-014-0801-x.Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2018. Электронный ресурс 10.03.2018г. Available from: http: //www.ginasthma.org/Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2018. Электронный ресурс 10.03.2018г. Available from: http: //www.ginasthma.org/Hekking PP, Wener RR, Amelink M et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol, 2015 Apr, 135(4): 896– 902.Hekking PP, Wener RR, Amelink M et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol, 2015 Apr, 135(4): 896– 902.Luskin AT, Chipps BE, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthmarelated quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract, 2014, 2(5): 544–552. doi: 10.1016/j.jaip.2014.02.011.Luskin AT, Chipps BE, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthmarelated quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract, 2014, 2(5): 544–552. doi: 10.1016/j.jaip.2014.02.011.Moore WC, Bleecker ER, Curran-Everett D et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol, 2007, 119: 405–413.Moore WC, Bleecker ER, Curran-Everett D et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol, 2007, 119: 405–413.Haldar P, Pavord I, Shaw D et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med, 2008, 178: 218–224.Haldar P, Pavord I, Shaw D et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med, 2008, 178: 218–224.Moore WC, Meyers DA, Wenzel SE et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med, 2010, 181: 315–323.Moore WC, Meyers DA, Wenzel SE et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med, 2010, 181: 315–323.Wenzel S. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Medicine, 2012, 18: 716–725.Wenzel S. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Medicine, 2012, 18: 716–725.Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nature Medicine, 2013, 19(8): 977.Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nature Medicine, 2013, 19(8): 977.Сергеева Г.Р., Емельянов А.В., Коровина О.В. и др. Тяжелая бронхиальная астма: характеристика пациентов в клинической практике. Терапевтический архив, 2015, 12: 22-27. doi: 10.1136/thx.2010,153643.Sergeeva GR, Emelyanov AV, Korovina OV. Severe bronchial asthma: characteristics of patients in clinical practice. Terapevticheskiy Arkhiv, 2015, 12: 22-27. doi: 10.1136/thx.2010,153643.Ненашева Н.М., Meyers A, Sun SX, Morimoto Y, Di Bonaventura M. Характеристика больных тяжелой неконтролируемой бронхиальной астмой в России. Сборник трудов XXVII Национального конгресса по болезням органов дыхания. Санкт-Петербург 17–20 октября 2017 г. М.: ДизайнПресс, 2017: 21-22.Nenasheva NM, Meyers A, Sun SX, Morimoto Y, Di Bonaventura M. Characteristics of patients with severe uncontrolled bronchial asthma in Russia. Collection of papers of the 27th National Respiratory Diseases Congress. St. Petersburg October 17–20, 2017 M .: DizainPress, 2017: 21-22Schleich F, Brusselle G, Louis R et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respiratory Medicine, 2014, 108: 1723–1732.Schleich F, Brusselle G, Louis R et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respiratory Medicine, 2014, 108: 1723–1732.Shau DE, Sousa AR, Fowler SJ, Fleming LJ, Robers G, et all. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J, 2015 Nov, 46(5): 1308-21. doi: 10.1183/13993003.00779-201.Shau DE, Sousa AR, Fowler SJ, Fleming LJ, Robers G, et all. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J, 2015 Nov, 46(5): 1308-21. doi: 10.1183/13993003.00779-201.Buhl R, Humbert M, Bjermer L et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J, 2017. 49: 1700634. doi: 10.1183/13993003.00634-2017.Buhl R, Humbert M, Bjermer L et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J, 2017. 49: 1700634. doi: 10.1183/13993003.00634-2017.Bousquet J, Chanez P, Lacoste JY, White R, Vic P, Godard P, Michel FB. Asthma: a disease remodeling the airways. Allergy, 1992 Feb, 47(1): 3-11.Bousquet J, Chanez P, Lacoste JY, White R, Vic P, Godard P, Michel FB. Asthma: a disease remodeling the airways. Allergy, 1992 Feb, 47(1): 3-11.Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol, 2009, 101: 81-121. doi: 10.1016/S0065-2776(08)01003-1.Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol, 2009, 101: 81-121. doi: 10.1016/S0065-2776(08)01003-1.Humbles AA, et al. A critical role for eosinophils in allergic airways remodeling. Science, 2004, 305: 1776–1779. doi: 10.1126/science.1100283.Humbles AA, et al. A critical role for eosinophils in allergic airways remodeling. Science, 2004, 305: 1776–1779. doi: 10.1126/science.1100283.Green RH, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet, 2002, 360: 1715–1721. doi: 10.1016/S0140-6736(02)11679-5.Green RH, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet, 2002, 360: 1715–1721. doi: 10.1016/S0140-6736(02)11679-5.Duncan CJ, Lawrie A, Blaylock MG, Douglas JG, Walsh GM. Reduced eosinophil apoptosis in induced sputum correlates with asthma severity. Eur Respir J, 2003, 22: 484–90.Duncan CJ, Lawrie A, Blaylock MG, Douglas JG, Walsh GM. Reduced eosinophil apoptosis in induced sputum correlates with asthma severity. Eur Respir J, 2003, 22: 484–90.Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med, 2015, 3: 849–858. doi: 10.1016/S22132600(15)00367-7.Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med, 2015, 3: 849–858. doi: 10.1016/S22132600(15)00367-7.Kupczyk M, ten Brinke A, Sterk P et al. Frequent exacerbators–a distinct phenotype of severe asthma. Clin Exp Allergy, 2014 Feb, 44(2): 21221. doi: 10.1111/cea.12179.Kupczyk M, ten Brinke A, Sterk P et al. Frequent exacerbators–a distinct phenotype of severe asthma. Clin Exp Allergy, 2014 Feb, 44(2): 21221. doi: 10.1111/cea.12179.van Veen IH, Ten Brinke A, Gauw SA, Sterk PJ, Rabe KF, Bel EH. Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol, 2009 Sep, 124(3): 615-7, 617.e1-2. doi: 10.1016/j.jaci.2009.06.029.van Veen IH, Ten Brinke A, Gauw SA, Sterk PJ, Rabe KF, Bel EH. Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol, 2009 Sep, 124(3): 615-7, 617.e1-2. doi: 10.1016/j.jaci.2009.06.029.Varricchi G et al. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol, 2016, 16: 186–200.Varricchi G et al. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol, 2016, 16: 186–200.Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet, 2000, 356: 2144–48.Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet, 2000, 356: 2144–48.Nair P, Pizzichini M, Kjarsgaard M et al. Mepolizumab for prednison-dependent asthma with sputum eosinophilia. N Engl J Med, 2009, 360: 985–993.Nair P, Pizzichini M, Kjarsgaard M et al. Mepolizumab for prednison-dependent asthma with sputum eosinophilia. N Engl J Med, 2009, 360: 985–993.Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med, 2009, 360: 973–84.Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med, 2009, 360: 973–84.Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebocontrolled trial. Lancet, 2012, 380: 651–9.Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebocontrolled trial. Lancet, 2012, 380: 651–9.Ortega HG, Liu MC, Pavord ID et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med, 2014, 371: 1198–1207.Ortega HG, Liu MC, Pavord ID et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med, 2014, 371: 1198–1207.Bel EH, Wenzel SE, Thompson PJ et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med, 2014, 371: 1189–1197.Bel EH, Wenzel SE, Thompson PJ et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med, 2014, 371: 1189–1197.Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multicenter, Open-label, Phase IIIb Study. Clin Ther, 2016 Sep, 38(9): 2058-2070.e1. doi: 10.1016/j.clinthera.2016.07.010.Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multicenter, Open-label, Phase IIIb Study. Clin Ther, 2016 Sep, 38(9): 2058-2070.e1. doi: 10.1016/j.clinthera.2016.07.010.Albers FC, Ortega H, Bradford ES, Gilson MJ, Price RG, Yancey SW, Moore W. Durability of clinical response following long-term treatment with mepolizumab in patients with severe eosinophilic asthma: the COLUMBA study. Presented at the American Thoracic Society International Conference, San Diego, CA, USA, May 18–23, 2018.Albers FC, Ortega H, Bradford ES, Gilson MJ, Price RG, Yancey SW, Moore W. Durability of clinical response following long-term treatment with mepolizumab in patients with severe eosinophilic asthma: the COLUMBA study. Presented at the American Thoracic Society International Conference, San Diego, CA, USA, May 18–23, 2018.Ortega HG, Albers FC, Bradford ES, Gilson MJ, Price RG, Yancey SW, Leigh R, Khatri S. Long-term Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: The COLUMBA Study. Presented at the American Thoracic Society International Conference, San Diego, CA, USA, May 18–23, 2018 Poster No. P892 (A1367).Ortega HG, Albers FC, Bradford ES, Gilson MJ, Price RG, Yancey SW, Leigh R, Khatri S. Long-term Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: The COLUMBA Study. Presented at the American Thoracic Society International Conference, San Diego, CA, USA, May 18–23, 2018 Poster No. P892 (A1367).Инструкция по медицинскому применению препарата Нукала.Patient Information Leaflet for Nucala

The authors declare that there are no conflicts of interest present.